This trial is active, not recruiting.

Condition hiv infections
Treatments nelfinavir mesylate, efavirenz, lamivudine, keyhole-limpet hemocyanin, stavudine, zidovudine, didanosine
Phase phase 4
Sponsor Agouron Pharmaceuticals
Start date December 1999
Trial size 200 participants
Trial identifier NCT00005000, 259H, AG1343-1127


The purpose of this study is to compare two drugs (nelfinavir [NFV] and efavirenz [EFV]) used in start-up anti-HIV treatment. Doctors want to see if one is better than the other in extending the time that viral load (level of HIV in the blood) is kept low. The study will also look at the response of the immune system to each drug.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Intervention model crossover assignment
Primary purpose treatment

Eligibility Criteria

Male or female participants of any age.

Inclusion Criteria Patients may be eligible for this trial if they: - Are HIV-positive. - Have a CD4 count of at least 100 cells/mm3. - Have a viral load of at least 5,000 copies/ml. Exclusion Criteria Patients may not be eligible for this study if they: - Have taken any antiretroviral (anti-HIV) agent.

Additional Information

Official title A Randomized, Open-Label, Study of Nelfinavir or Efavirenz in HIV-1 Infected, Antiretroviral Naive Patients
Description Patients are randomized to initiate therapy and receive either nelfinavir (NFV) or efavirenz (EFV) in the first regimen (R1). All patients also receive zidovudine (AZT) and lamivudine (3TC). Patients are further randomized in a factorial fashion and by stratification based on HIV RNA level (less than 10,000, 10,000-100,000, or greater than 100,000 copies/ml) to be administered a single injection of a neo-antigen (KLH) at Week 12, 24, or 48. Therapy continues until switch criteria are met either before or after Week 24. When switch criteria are met, patients advance to the next regimen (R2). R2 patients previously taking NFV switch to EFV; those randomized to EFV switch to NFV; the additional NRTIs change to stavudine (d4T) and didanosine (ddI). Therapy is continued for an additional 24 weeks.
Trial information was received from ClinicalTrials.gov and was last updated in June 2005.
Information provided to ClinicalTrials.gov by NIH AIDS Clinical Trials Information Service.